Previous 10 | Next 10 |
Stealth BioTherapeutics to Present at Upcoming March Investor Conferences PR Newswire BOSTON , March 9, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and comm...
NEW YORK, March 08, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10 th . This virtual event will showcase live company presentations and intera...
Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit PR Newswire BOSTON , Feb. 22, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and co...
Stealth BioTherapeutics (NASDAQ:MITO) said the final patient in its ReCLAIM-2 phase 2 trial of elamipretide for extra-foveal geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) completed treatment. GA is an advanced form of AMD, a leading ca...
Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial PR Newswire BOSTON , Feb. 15, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, ...
Stealth BioTherapeutics Receives Nasdaq Notification Regarding Minimum Market Value Of Publicly Held Shares Requirement PR Newswire BOSTON , Feb. 11, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company f...
Stealth BioTherapeutics Announces Oral Presentation of New Duchenne Muscular Dystrophy Data at the 2022 Muscular Dystrophy Association Clinical and Scientific Conference PR Newswire BOSTON , Feb. 8, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO)...
Stealth BioTherapetuics Receives Nasdaq Notifications Regarding Minimum Bid And Market Value Requirements PR Newswire BOSTON , Jan. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery...
Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference PR Newswire BOSTON , Jan. 4, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, a...
Stealth BioTherapeutics Reports Positive Pre-IND Meeting for Duchenne Muscular Dystrophy Alignment reached on key aspects of development program and trial design including potential utility of proposed surrogate endpoint; IND submission planned PR Newswire BOSTON ...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp. Website:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...